{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:04:19Z","timestamp":1770228259322,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12916-016-0732-1","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T16:17:24Z","timestamp":1478708244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Gout: will the \u201cKing of Diseases\u201d be the first rheumatic disease to be cured?"],"prefix":"10.1186","volume":"14","author":[{"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"issue":"10","key":"732_CR1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"732_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"732_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","volume":"18","author":"M Dehlin","year":"2016","unstructured":"Dehlin M, Drivelegka P, Sigurdardottir V, Svard A, Jacobsson LT. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016;18:164.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"732_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-014-0200-8","volume":"12","author":"AD Lopez","year":"2014","unstructured":"Lopez AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, et al. Remembering the forgotten non-communicable diseases. BMC Med. 2014;12(1):200.","journal-title":"BMC Med"},{"key":"732_CR5","first-page":"39","volume":"4","author":"SR Kingsbury","year":"2011","unstructured":"Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39\u201349.","journal-title":"J Inflamm Res"},{"issue":"7081","key":"732_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341.","journal-title":"Nature"},{"issue":"10","key":"732_CR7","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1002\/art.22938","volume":"56","author":"RM Pope","year":"2007","unstructured":"Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007;56(10):3183\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"732_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/art.24185","volume":"60","author":"WJ Martin","year":"2009","unstructured":"Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 2009;60(1):281\u20139.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"732_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/ard.2009.109355","volume":"68","author":"R Torres","year":"2009","unstructured":"Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;68(10):1602\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"732_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/ard.2007.073759","volume":"66","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis. 2007;66(12):1683\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"732_CR11","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"732_CR12","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"732_CR13","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 2015;67(10):2557\u201368.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"732_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/rheumatology\/ket341","volume":"53","author":"M Gruber","year":"2014","unstructured":"Gruber M, Bodner G, Rath E, Supp G, Weber M, Schueller-Weidekamm C. Dual-energy computed tomography compared with ultrasound in the diagnosis of gout. Rheumatology. 2014;53(1):173\u20139.","journal-title":"Rheumatology"},{"issue":"7","key":"732_CR15","doi-asserted-by":"publisher","first-page":"E344","DOI":"10.1055\/s-0032-1325388","volume":"33","author":"F Ruiz Santiago","year":"2012","unstructured":"Ruiz Santiago F, Guzman Alvarez L, Del Mar Castellano Garcia M. Ultrasound pathology of the elbow: a pictorial essay. Ultraschall Med. 2012;33(7):E344\u20139.","journal-title":"Ultraschall Med"},{"issue":"2","key":"732_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1148\/radiol.11102485","volume":"261","author":"KN Glazebrook","year":"2011","unstructured":"Glazebrook KN, Guimaraes LS, Murthy NS, Black DF, Bongartz T, Manek NJ, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261(2):516\u201324.","journal-title":"Radiology"},{"issue":"3","key":"732_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3899\/jrheum.140634","volume":"42","author":"C Loffler","year":"2015","unstructured":"Loffler C, Sattler H, Peters L, Loffler U, Uppenkamp M, Bergner R. Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. J Rheumatol. 2015;42(3):513\u201320.","journal-title":"J Rheumatol"},{"issue":"3","key":"732_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3899\/jrheum.141322","volume":"42","author":"JA Singh","year":"2015","unstructured":"Singh JA, Dalbeth N. Is the double contour sign specific for gout? Or only for crystal arthritis? J Rheumatol. 2015;42(3):353\u20134.","journal-title":"J Rheumatol"},{"issue":"10","key":"732_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"732_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"key":"732_CR21","doi-asserted-by":"crossref","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016. Ahead of print.","DOI":"10.1136\/annrheumdis-2016-209707"},{"issue":"2","key":"732_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11926-009-0022-4","volume":"11","author":"JA Singh","year":"2009","unstructured":"Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009;11(2):154\u201360.","journal-title":"Curr Rheumatol Rep"},{"key":"732_CR23","doi-asserted-by":"crossref","unstructured":"Neogi T, Dalbeth N, Stamp L, Castelar G, Fitzgerald J, Gaffo A, et al. Renal dosing of allopurinol results in suboptimal gout care. Ann Rheum Dis. 2016. Ahead of print.","DOI":"10.1136\/annrheumdis-2016-210352"},{"issue":"8","key":"732_CR24","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"key":"732_CR25","doi-asserted-by":"crossref","unstructured":"Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016. Ahead of print.","DOI":"10.1136\/annrheumdis-2016-209467"},{"issue":"6","key":"732_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"1","key":"732_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"732_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u20135.","journal-title":"Arthritis Rheum"},{"issue":"23","key":"732_CR29","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"7","key":"732_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711\u201320.","journal-title":"JAMA"},{"key":"732_CR31","volume-title":"Management of Gout. Executive Summary","author":"Effective Health Care Program","year":"2016","unstructured":"Effective Health Care Program. Management of Gout. Executive Summary. Rockville: Agency for Healthcare Research and Quality; 2016. https:\/\/effectivehealthcare.ahrq.gov\/ehc\/products\/564\/2196\/gout-management-executive-160314.pdf ."},{"issue":"8","key":"732_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1517\/13543784.2015.1051617","volume":"24","author":"H Shahid","year":"2015","unstructured":"Shahid H, Singh JA. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24(8):1013\u201330.","journal-title":"Expert Opin Investig Drugs"},{"key":"732_CR33","volume-title":"FDA approves Zurampic to treat high blood uric acid levels associated with gout","author":"FDA news release","year":"2015","unstructured":"FDA news release. FDA approves Zurampic to treat high blood uric acid levels associated with gout. 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm478791.htm. Accessed 10 Jan 2016."},{"key":"732_CR34","unstructured":"European Medicines Agency. Zurampic. Lesinurad. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003932\/human_med_001963.jsp&mid=WC0b01ac058001d124 . Accessed 10 Jan 2016."},{"issue":"6","key":"732_CR35","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI42344","volume":"120","author":"A So","year":"2010","unstructured":"So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120(6):1791\u20139.","journal-title":"J Clin Invest"},{"key":"732_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840.Aheadofprint","author":"KG Saag","year":"2016","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (A US-based Study). Arthritis Rheumatol. 2016. doi: 10.1002\/art.39840.Aheadofprint .","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"732_CR37","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68(8):2027\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"732_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960\u20136.","journal-title":"Ann Rheum Dis"},{"key":"732_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2474-12-103","volume":"12","author":"P Primatesta","year":"2011","unstructured":"Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"732_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679\u201387. e671.","journal-title":"Am J Med"},{"issue":"9","key":"732_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/heartjnl-2014-306670","volume":"101","author":"FJ Abajo de","year":"2015","unstructured":"de Abajo FJ, Gil MJ, Rodriguez A, Garcia-Poza P, Alvarez A, Bryant V, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101(9):679\u201385.","journal-title":"Heart"},{"key":"732_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58.","journal-title":"BMC Nephrol"},{"issue":"4","key":"732_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","volume":"13","author":"DM Maahs","year":"2013","unstructured":"Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13(4):550\u20139.","journal-title":"Curr Diab Rep"},{"issue":"8","key":"732_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3346\/jkms.2014.29.8.1077","volume":"29","author":"HA Kim","year":"2014","unstructured":"Kim HA, Seo YI, Song YW. Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J Korean Med Sci. 2014;29(8):1077\u201381.","journal-title":"J Korean Med Sci"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-016-0732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-016-0732-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-016-0732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T12:05:29Z","timestamp":1568549129000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-016-0732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1186\/s12916-016-0732-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]},"article-number":"180"}}